Seoul Pharma

At a glance

Seoul Pharma filed 21 disclosures in the last 12 months, including 1 insider and 1 5% holder. The most recent key filing was on Apr 1.

Revenue for 2025 was ₩52.1B, down 2.7% on 2024. It made an operating loss of ₩1.3B. Debt was 75% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩23.8B and operating loss of ₩528.9M.

The 2025 annual report lists 132 employees with an average tenure of 5.7 years and average pay of ₩65.8M, #733 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩36.6M each on average. It paid no cash dividend for 2025. 2018큐씨피13호 사모투자합자회사 and related parties held 59.41% at year end.

From the 2025 annual report

Staff: 132 (71 men, 61 women), of whom 4 on fixed-term contracts. Total pay for the year: ₩8.7B. Directors and auditors: 8, paid ₩293.2M in total.

No cash dividend was paid for 2025.

Largest shareholder

2018큐씨피13호 사모투자합자회사 holds 59.41%; with 0 related parties the group holds 59.41% of common shares at year end.

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary